Clinical Risk Assessments Considerations for Immunogenicity & Tolerogenicity for LNP Vectored Therapeutics Vaccine
Time: 9:00 am
day: Day One
Details:
- Evaluating the potential for the LNP vector to induce antigen-presenting cells that may trigger unwanted immune responses
- Analyzing the likelihood of the vaccine inducing the production of antibodies against the therapeutic antigen
- Understanding the persistence of the tolerogenic response induced by the LNP-based vaccine over time
